Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRAX Praxis Precision Medicines, Inc.

盘前交易 06-10 08:50:28 EDT

250.33

-2.92

-1.15%

盘前245.00

-5.33-2.13%

08:12 EDT

最高266.60	最低244.16	成交量46.55万
今开258.10	昨收253.25	日振幅8.86%
总市值69.72亿	流通市值64.53亿	总股本2,785万
成交额1.17亿	换手率1.81%	流通股本2,578万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":250.33,"timestamp":1781035200000,"preClose":253.25,"halted":0,"volume":465503,"hourTrading":{"tag":"盘前","latestPrice":245,"preClose":250.33,"latestTime":"08:12 EDT","volume":71,"amount":17241.79052,"timestamp":1781093543229,"change":-5.33,"changeRate":-0.021292,"amplitude":0.015539},"delay":0,"changeRate":-0.011530108588351382,"floatShares":25778700,"shares":27850833,"eps":-13.34879,"marketStatus":"盘前交易","change":-2.92,"latestTime":"06-10 08:50:28 EDT","open":258.1,"high":266.6,"low":244.16,"amount":116754767.19763,"amplitude":0.088608,"askPrice":266.99,"askSize":7,"bidPrice":240,"bidSize":35,"shortable":3,"etf":0,"ttmEps":-13.34879,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781098200000},"marketStatusCode":1,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":250.33,"preHourTrading":{"tag":"盘前","latestPrice":245,"preClose":250.33,"latestTime":"08:12 EDT","volume":71,"amount":17241.79052,"timestamp":1781093543229,"change":-5.33,"changeRate":-0.021292,"amplitude":0.015539},"postHourTrading":{"tag":"盘后","latestPrice":245,"preClose":250.33,"latestTime":"19:10 EDT","volume":39136,"amount":9794467.18,"timestamp":1781046644163,"change":-5.33,"changeRate":-0.021292,"amplitude":0.021292},"volumeRatio":0.49790325792393586,"impliedVol":0.6335,"impliedVolPercentile":0.044},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"1198928830","title":"异动解读｜Praxis Precision Medicines盘中下跌5.17%，核心癫痫临床试验主要终点失败影响持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1198928830","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198928830?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:30","pubTimestamp":1780583405,"startTime":"0","endTime":"0","summary":"6月4日，Praxis Precision Medicines盘中下跌5.17%，报272.1美元/股，成交额6508.06万美元。尽管试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，且核心药物Vormatrigine因不良事件停药率低于10%、耐受性良好，股价曾出现短暂反弹，但主要终点失败对公司核心管线构成的重大挑战仍在持续压制市场信心。对于临床阶段生物制药公司而言，关键试验主要终点未达标意味着后续开发路径面临高度不确定性，市场情绪尚未完全消化该利空影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126025209","title":"异动解读｜Praxis Precision Medicines盘中上涨5.31%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1126025209","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126025209?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:31","pubTimestamp":1780497086,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘中上涨5.31%，报271.78美元/股，成交额4320.95万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，股价一度大跌逾15%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时核心药物Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性为后续临床开发保留路径，推动股价持续反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173943333","title":"异动解读｜Praxis Precision Medicines盘前上涨5.7%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1173943333","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173943333?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:03","pubTimestamp":1780473786,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘前上涨5.7%，报273.0美元/股，成交额6.37万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，盘中一度大跌15.36%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时核心药物Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性为后续临床开发保留路径，推动股价持续反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116005873","title":"异动解读｜Praxis Precision Medicines夜盘上涨7.39%，核心癫痫试验次要终点积极信号推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1116005873","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116005873?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:29","pubTimestamp":1780457359,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines夜盘上涨7.39%，报277.15美元/股，成交额7.77万美元。消息面上，公司此前公布Power1研究结果，虽针对难治性局灶性发作癫痫的主要终点未达标，盘中一度大跌15.36%，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，同时Vormatrigine因不良事件停药率低于10%，耐受性良好。市场在消化主要终点失败冲击后，次要终点积极数据及良好安全性推动股价出现技术性反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129219975","title":"异动解读｜Praxis Precision Medicines盘后下跌8.94%，核心癫痫临床试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1129219975","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129219975?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:23","pubTimestamp":1780431799,"startTime":"0","endTime":"0","summary":"6月3日，Praxis Precision Medicines盘后下跌8.94%，报258.59美元/股，成交额21.2万美元。消息面上，公司宣布其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点，这一结果对公司核心管线构成重大挑战。对于临床阶段的生物制药公司而言，关键试验主要终点未达标通常意味着后续开发路径面临高度不确定性。但次要终点的积极信号未能抵消主要终点失败带来的市场担忧，股价在盘中大跌15.36%后盘后继续走低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182307151","title":"异动解读｜Praxis Precision Medicines盘中下跌15.36%，核心癫痫临床试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1182307151","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182307151?lang=zh_cn&edition=full","pubTime":"2026-06-03 00:13","pubTimestamp":1780416798,"startTime":"0","endTime":"0","summary":"6月2日，Praxis Precision Medicines盘中下跌15.36%，报283.47美元/股，成交额2.07亿美元。消息面上，公司宣布其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点，这一结果对公司核心管线构成重大挑战。对于临床阶段的生物制药公司而言，关键试验主要终点未达标通常意味着后续开发路径面临不确定性，市场对此反应剧烈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177523657","title":"Praxis Precision Medicines新药Vormatrigine耐受性良好，不良事件停药率低于10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177523657","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177523657?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345035,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其研发的药物Vormatrigine在临床试验中展现出良好的耐受性。数据显示，因不良事件而停止用药的患者比例被控制在10%以下，这一结果令人鼓舞。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","PRAX","BK4139","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146218009","title":"Praxis Precision Medicines达到次要终点50%应答率 30毫克剂量组癫痫发作减少更显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1146218009","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146218009?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345035,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. 宣布其临床试验达到了关键的次要终点，即50%的应答率。数据显示，在降低癫痫发作频率方面，30毫克剂量组展现出了更为显著的效果。这一发现突显了该剂量在疗效上的优势，为后续的临床开发提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160185701","title":"Praxis Precision Medicines公司Power1研究在难治性局灶性发作癫痫中未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1160185701","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160185701?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:17","pubTimestamp":1780345034,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点。该结果对公司的相关研发项目构成了挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE0009355771.USD","BK4139","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146879586","title":"Praxis Precision Medicines公布企业动态及2026年第一季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1146879586","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146879586?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155288,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.近日同步披露了公司最新运营进展与2026财年首季度财务报告。此次公告涵盖公司核心研发管线推进情况、关键业务里程碑及当期财务数据，为投资者提供全面战略透视。财务结果显示，公司在精准神经科学疗法领域的投入持续深化，多项临床阶段项目取得突破性进展。管理层在财报中强调，将加速推进针对遗传性癫痫疾病的创新疗法全球化布局，同时通过优化资本结构提升长期竞争力。此次季度业绩的发布，标志着Praxis在精准医疗领域战略执行进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4139","PRAX","LU0109394709.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172675456","title":"Praxis Precision Medicines, Inc.：FDA将Ulixacaltamide的PDUFA目标行动日期定为2027年1月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=1172675456","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172675456?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:30","pubTimestamp":1776166250,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已为Praxis Precision Medicines, Inc.旗下的在研药物Ulixacaltamide，设定了处方药使用者付费法案（PDUFA）的目标行动日期，定于2027年1月29日。这一日期标志着FDA完成对该药物新药申请审查的目标时间点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","PRAX","IE00B2B36J28.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132558277","title":"Praxis Precision Medicines宣布FDA受理盐酸Ulixacaltamide治疗特发性震颤的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1132558277","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132558277?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:30","pubTimestamp":1776166242,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，美国食品药品监督管理局（FDA）已正式受理其针对特发性震颤患者的新药申请，该申请涉及药物盐酸Ulixacaltamide。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","PRAX","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158299786","title":"Praxis Precision Medicines公司：Elsunersen在最高8毫克剂量下耐受性良好，未出现药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1158299786","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158299786?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:03","pubTimestamp":1775477038,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其研究药物Elsunersen在临床试验中表现出良好的耐受性。数据显示，在剂量递增至8毫克的范围内，未观察到任何与药物相关的严重不良事件。这一结果进一步支持了该候选药物的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","PRAX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","IE0009355771.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112964089","title":"Praxis精准医疗公布Elsunersen治疗SCN2A早发性发育性癫痫性脑病的Embrave试验A部分积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112964089","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112964089?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:01","pubTimestamp":1775476874,"startTime":"0","endTime":"0","summary":"Praxis精准医疗公司近日宣布，其针对SCN2A早发性发育性癫痫性脑病研发的药物Elsunersen，在Embrave临床试验的A阶段取得了积极的研究成果。该试验数据表明，Elsunersen在目标患者群体中展现出良好的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","PRAX","IE00B2B36J28.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191234265","title":"Praxis Precision Medicines公司宣布：FDA为Relutrigine设定PDUFA目标行动日期为2026年9月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1191234265","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191234265?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:02","pubTimestamp":1774900932,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司披露，美国食品药品监督管理局（FDA）已为其在研药物Relutrigine设定了处方药使用者费法案（PDUFA）的目标行动日期，定于2026年9月27日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154860007","title":"Praxis Precision Medicines公司Relutrigine治疗广泛性癫痫的Emerald试验预计2026年底完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1154860007","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154860007?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:02","pubTimestamp":1774900930,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司近日公布，其研发的Relutrigine针对广泛性癫痫适应症的Emerald临床试验，预计将于2026年底前完成。该试验的进展备受市场关注，其结果将对公司未来发展产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","PRAX","IE00BJT1NW94.SGD","IE0009355771.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180757495","title":"Praxis Precision Medicines公布公司最新动态及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1180757495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180757495?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:31","pubTimestamp":1771504278,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.（简称Praxis）近日披露了公司运营进展及2025年第四季度与全年财务报告。此次公告涵盖关键业务里程碑与财务数据，为投资者提供全面战略视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","PRAX","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","LU0889565916.HKD","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105033186","title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","url":"https://stock-news.laohu8.com/highlight/detail?id=1105033186","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105033186?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:44","pubTimestamp":1770864278,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.将于2026年02月19日发布最新财报，市场关注其本季度营收与利润拐点的可见性以及研发推进节奏对亏损收窄的影响。由于当前缺乏披露毛利率与净利率的预测口径，相关指标暂无一致预估。上一财季管理层未提供可量化的本季度营收、毛利率、净利润或净利率、调整后每股收益等预测口径。基于公开渠道收集的区间内观点，机构对Praxis Precision Medicines, Inc.的态度以审慎偏中性为主，尚未形成明确的一边倒看多或看空共识。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157558681","title":"富国银行首次覆盖Praxis Precision Medicines 给予持股观望评级 目标价282美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157558681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157558681?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:36","pubTimestamp":1770035783,"startTime":"0","endTime":"0","summary":"富国银行发布最新研报，宣布对精准医疗公司Praxis Precision Medicines, Inc. (PRAX) 启动覆盖研究。该机构给予该公司\"持股观望\"评级，同时设定目标股价为每股282美元。\n此次覆盖标志着华尔街对这家生物技术企业的关注度提升。分析师在报告中指出，虽然公司在新药研发领域展现潜力，但当前估值已基本反映其成长前景，因此建议投资者保持谨慎乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B2B36J28.USD","BK4139","PRAX","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128938615","title":"Praxis Precision Medicines任命全球癫痫领域权威Orrin Devinsky博士担任临床战略负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=1128938615","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128938615?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:31","pubTimestamp":1768339876,"startTime":"0","endTime":"0","summary":"精准医疗公司Praxis Precision Medicines, Inc.宣布一项重要人事任命：全球癫痫治疗领域的顶尖专家Orrin Devinsky博士正式加入公司，出任临床战略负责人。这一战略布局彰显了Praxis深耕神经系统疾病治疗领域的决心。此次任命被视为Praxis加速推进其神经科学管线的重要里程碑。公司表示，Devinsky博士的专业洞察将直接应用于核心项目的临床开发路径优化，助力提升临床试验效率与成功率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4139","PRAX","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.2415},{"period":"3month","weight":-0.1571},{"period":"6month","weight":-0.0634},{"period":"1year","weight":4.6241},{"period":"ytd","weight":-0.1507}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Praxis Precision Medicines, Inc.于2015年9月22日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，将遗传见解转化为中枢神经系统（CNS）治疗方法的发展，CNS是以神经元失衡为特征的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.017086},{"month":5,"riseRate":0.5,"avgChangeRate":-0.087139},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.126103},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}